ClinicalTrials.gg
RecruitingNCT05660642Updated Jul 6, 2026

An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression

A Phase 2 interventional study of BPL-003 in Treatment Resistant Depression, sponsored by Beckley Psytech Limited. Recruiting at 3 sites in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Beckley Psytech Limited (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Depressive Disorder, Treatment-Resistant with a site in United Kingdom — 6 open to participants now, 7 under way, 2 of them phase 3. Depressive Disorder, Treatment-Resistant · United Kingdom.

Planned enrollment
13th of 21
72 · median 139
Started
2023
with 2 others
Phase 2
6 of 26
2 open now
Registered
18th of 26
by date
Lead sponsor
2 of 26
Beckley Psytech Limited

Among the 26 studies in Depressive Disorder, Treatment-Resistant with a site in United Kingdom, this one is the 13th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2023, is one of 6 in phase 2, and was the 18th registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

6 of the 26 studies in Depressive Disorder, Treatment-Resistant with a site in United Kingdom are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Depressive Disorder, Treatment-Resistant with a site in United Kingdom, or all of them as a file.
02

Study summary

An open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamics of one and two doses of intranasal BPL-003 combined with psychological support, in patients with treatment resistant depression when administered as monotherapy or as adjunctive therapy with defined SSRIs (citalopram, escitalopram, sertraline or fluoxetine).

Read the detailed description

Part 1: Up to 32 patients, across 2 parallel arms (Arms A and Arms B) will receive one of two single doses of BPL-003, given intranasally, with 12 weeks of follow-up assessments.

Part 2: Up to 40 patients, across 2 parallel arms (Arms A and Arms B) will receive two doses of BPL-003, given intranasally, with 10 weeks of follow-up assessments.

Psychological support will be given before, during and after dosing in Part 1 and Part 2.

03

Conditions studied

  • Treatment Resistant Depression
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with Major Depressive Disorder.
  2. Diagnosed with TRD defined as failure to respond to an adequate dose and duration of at least 2 pharmacological treatments in the past 5 years prior to screening, at least one of which is during the current episode.
  3. Montgomery-Asberg Depression Rating Scale score ≥24 at Screening.
  4. Clinical Global Impression - Severity ≥4 at Screening.
  5. Willing and able to discontinue current pharmacological anti-depressant therapy.
  6. On current stable dose of pharmacological antidepressant therapy limited to one of 4 SSRIs (Arm B), i.e. either citalopram, escitalopram, sertraline or fluoxetine.

Exclusion criteria

Exclusion Criteria:

  1. Current or history of schizophrenia, psychotic disorder including psychotic depression, bipolar disorder, delusional disorder, schizoaffective disorder, or any other severe psychiatric disorder.
  2. Current personality disorders.
  3. First-degree family history of schizophrenia, bipolar disorder, delusional disorder, personality disorders or schizoaffective disorder.
  4. Current alcohol or substance use disorder (other than caffeine or nicotine).
  5. A participant who at any time, has been unresponsive to ketamine, esketamine, an adequate course of treatment with electroconvulsive therapy, or has received vagal nerve stimulation or deep brain stimulation.
  6. Suicidal ideation with the intent to act or suicidal behaviour within the 12 months prior to the start of Screening or on Day 1 prior to dosing.
  7. Suicide attempt and/or self-injurious behaviour within the last 12 months prior to Screening.
  8. Uncontrolled medical conditions e.g. hypo/hyperthyroidism, diabetes, renal failure.
  9. Seizure disorder or history of seizures (including febrile seizures).
  10. Abnormal and results on the physical examination, vital signs, , or laboratory tests at Screening Baseline.
  11. Any nasal obstruction, blockage, or symptoms of congestion at the time of dosing, that in the Investigator's opinion may interfere with administration of the study drug.
  12. Currently receiving lithium, antipsychotics, serotonergic drugs (excluding the permitted SSRIs for arm B), psychostimulants, or any other prohibited medication.
  13. Female patients who are pregnant or lactating, or of and not willing to use adequate forms of .
  14. Male patients who are sexually active and not willing to using adequate forms of contraception.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Arm A

    Drug: BPL-003

  • Experimental
    Arm B

    Drug: BPL-003

Interventions

  • Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)

06

What researchers measure

Primary outcomes

  1. 1. To assess the safety and tolerability of single or multiple intranasal doses of BPL-003 in patients with treatment resistant depression

    * Percentage of patients with treatment emergent adverse events * Percentage of patients with clinically significant abnormal laboratory tests * Percentage of patients with clinically significant abnormal vital signs * Percentage of patients with clinically significant findings in physical examination * Percentage of patients with clinically significant ECG parameters or cardiac telemetry abnormalities (Part 1 Arm B only) * Percentage of patients with suicidal ideation or behaviour

    Time frame: Baseline to 12 weeks post dose

Other outcomes

  1. Change from Baseline in MADRS

    Time frame: Day 2 to 12 weeks post dose

  2. Percentage of responders

    Defined as 50% reduction in MADRS score compared to Baseline

    Time frame: Day 2 to 12 weeks post dose

  3. Percentage of patients in remission

    Defined as MADRS score of \<11

    Time frame: Day 2 to 12 weeks post dose

  4. Plasma levels of 5-MeO-DMT and its metabolites

    Time frame: Day 1

07

Study locations

2 of 3 sites recruiting
  • MAC Clinical Research
    Liverpool, L34 1BH, United Kingdom
    Recruiting
  • Hammersmith Medicines Research
    London, United Kingdom
    Recruiting
  • King's College London, Clinical Trials Facility
    London, United Kingdom
    Completed

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: No — Due to the UK GDPR, individual participant data will not be shared publicly. Group data will be presented in publication after study completion.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Nov 2026, 45 months after the start.

Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's planned 45 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2022
First posted
Dec 21, 2022
StartActual
Feb 10, 2023
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05660642
Responsible party
Sponsor
First posted
Dec 21, 2022
Start date
Feb 10, 2023
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jul 6, 2026

Study contacts

Kevin Craig, M.D.
Contact
clinicaltrials@ataibeckley.com
332-282-0507 ext. 1
Kevin Craig, M.D.
study director · Beckley Psytech Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BPL-003

Start the discussion